Analysis of the effect of halofuginone on bleomycin-induced scleroderma.
Yamamoto
T
T
Nishioka
K
K
D000818:Animals; D001761:Bleomycin / Q000633:toxicity; D003094:Collagen / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D051379:Mice; D010880:Piperidines; D011500:Protein Synthesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use*; D052999:Quinazolinones; D012595:Scleroderma, Systemic / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013047:Specific Pathogen-Free Organisms; D016896:Treatment Outcome
D010880:Piperidines; D011500:Protein Synthesis Inhibitors; D011799:Quinazolines; D052999:Quinazolinones; D001761:Bleomycin; D003094:Collagen; C010176:halofuginone